07:00 , Aug 1, 2016 |  BioCentury  |  Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

MVA-BN Filo: Phase I started

Bavarian Nordic said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from ...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

cAd3-EBO: Phase I data

An open-label, U.S. Phase I trial in 20 healthy adult volunteers showed that 2*1010 and 2*1011 particle-unit doses of intramuscular cAd3-EBO were well tolerated and induced glycoprotein-specific antibodies in all subjects. Reactogenicity and immune responses...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

cAd3-EBO Z: Phase Ib started

The University of Maryland, the Center for Vaccine Development of Mali and the Malian Ministry of Health began an open-label, dose-escalation Phase Ib trial to evaluate 2 dose levels of intramuscular cAd3-EBO Z in...